💸 The Tape

Hostile takeovers have a rhythm. First the bid, then the rejection, then the letter to shareholders, and then — when the bidder decides the board isn't going to pick up the phone — the fact sheet. Curaleaf (TSX: CURA) (OTCQX: CURLF) reached that stage Monday, releasing a fourteen-point "myth versus fact" document aimed squarely at Aurora Cannabis (NASDAQ: ACB) shareholders, along with a dedicated campaign site. The tone has shifted from "we'd like to engage" to "here is why your management is wrong about everything."

The core argument: results versus promises

Curaleaf's framing is simple. Aurora's board has told shareholders that the US$4.00 offer significantly undervalues the company. Curaleaf's response is to ask who exactly has been creating value. It tallies roughly C$5 billion in impairments and about C$130 million in "business transformation" costs under current management, alongside more than C$480 million of cumulative negative operating cash flow since fiscal 2021. It contrasts that with its own $447 million of positive operating cash flow over the same window, and points to a 97% share price decline during CEO Miguel Martin's tenure. Blunt, but every number is pulled from Aurora's own filings.

The sharpest jab is the one Curaleaf has been repeating since last week: Aurora's at-the-market program. The board keeps selling stock at prices below the offer while telling shareholders not to tender at the offer. Curaleaf now says those issuances have accelerated since the bid was launched. In any takeover fight, the target's own capital markets behavior is evidence, and Aurora's is doing Curaleaf's work for it.

Dismantling Aurora's defenses one at a time

On the "debt-free balance sheet" argument, Curaleaf offers a line that will get quoted for years: "Debt can be repaid; dilution is forever." Its point is that Aurora's cash pile was assembled through more than US$400 million of equity issuance since September 2020, so the "strength" Aurora is defending is the residue of shareholder dilution, not cash generation.

On the overvalued Curaleaf stock argument, Curaleaf quotes Aurora's own financial advisor, whose inadequacy opinion apparently states that Curaleaf's trading price "can be reasonably regarded as a proxy for underlying value." Aurora, Curaleaf says, can't simultaneously argue that Curaleaf's stock is inflated and that it's not worth enough.

On the US$5.00 cap, the position is that if Aurora's board actually cares about capped upside, it can shorten the 105-day bid window to 35 days and negotiate. Curaleaf notes the cap sits in the 92nd percentile of Canadian M&A premiums over the past decade and that Aurora used the same structure in its own hostile bidding days.

On governance and Boris Jordan's multi-voting control, Curaleaf leans on alignment rather than structure: insiders have nearly US$500 million invested, roughly 20% ownership versus about 1% at Aurora, and Aurora's insiders stand to collect about 10% of the transaction value in change-of-control payments. It name-checks Alphabet, Meta, Shopify, Green Thumb and Trulieve as multi-class peers.

The most consequential disclosure is buried in the middle: Curaleaf says Aurora never signed a confidentiality agreement and never once discussed price. If true, the board rejected the offer without testing whether a higher number existed, which is exactly the kind of process failure a special committee is supposed to avoid.

The U.S. exposure question

Aurora's circular framed Curaleaf's American adult-use business as federally illegal and therefore a risk to Aurora holders. Curaleaf flips it: roughly 60% of its U.S. business is medical, which since April sits in Schedule III and outside 280E, and the rest is exposure to the largest cannabis market on earth in a regulatory environment moving in one direction. It also addresses the Nasdaq-versus-OTC objection directly, noting Curaleaf has traded more dollar value on the TSX this year than Aurora has on Nasdaq, and that a U.S. exchange listing is expected once rescheduling wraps.

Reading between the lines

Three things stand out. First, Curaleaf keeps inviting a counter. Every section ends with a version of "engage with us," which means the bidder has room above $4.00 and is waiting for Aurora to name a number. Second, the document is built for Canadian proxy advisors and institutional holders, not retail: percentile rankings, insider alignment, process critique. That's the audience that decides a contested bid. Third, Aurora's silence is now the story. A spokesperson told StratCann last month the company won't comment further unless disclosure is required, which is defensible legally and terrible tactically when the other side is publishing a new attack every week.

Aurora's best counter remains the one it hasn't made: a real sum-of-the-parts case for its EU-GMP medical platform, Bevo preferred stake and roughly US$2 per share in cash, backed by either a competing bid or a capital return. Until it produces one, Curaleaf gets to define the debate as "a 45% premium versus a management team that's diluted you for six years," and that's a debate Aurora loses on the tender count.

Shareholders have until December 1 to decide. Given the pace of escalation, expect Aurora to respond within days — and expect the number to move before the deadline does.

📈 Dog Walkers

$CMPS ( ▲ 5.8% ) Reports Topline Durability Data

Compass Pathways (Nasdaq: CMPS) released topline 52-week results from Part C of its Phase 3 COMP005 trial this morning, and the headline is the number regulators and payers have been waiting on: patients randomized to the 25 mg arm who received an additional dose in the open-label extension showed an average 13-point reduction in MADRS score from baseline at Week 52. That's a treatment-resistant depression population — people who have failed at least two prior antidepressants — holding a clinically meaningful response for a full year on one or two administrations of synthetic psilocybin.

The second finding is arguably more useful commercially. Placebo patients who crossed over and received their first 25 mg dose in Part C reproduced the pattern seen in the blinded portion of the trial: rapid onset, meaningful effect, durable benefit. In other words, the drug did the same thing in a fresh cohort, at a different point in the study, outside the controlled phase. Safety in Part C was consistent with Parts A and B, with no new findings.

Compass says its rolling NDA is underway and final submission remains on track for Q4 2026, with a commercial launch targeted for the first half of 2027. The timing isn't accidental: the company is at Cantor's healthcare conference today, just debuted a U.S. physician education campaign at Psych Congress, and is presenting health-economics data alongside it. This is a company behaving like a launch is coming.

What it means going forward

The obvious caveat first: Part C is open-label, so the 13-point number carries the usual expectation bias and can't be read like the blinded six-week data. The FDA knows that, and so does everyone on the investor call. What the data does is answer the question that has hung over psychedelic medicine since the Lykos rejection: does the effect last, and what does re-dosing do? The answer appears to be "yes" and "it deepens the response," which turns COMP360 from a one-shot intervention into something that can be modeled as a maintenance regimen.

That reframing matters in three places. For payers, a treatment given once or twice a year with a year of durability is a fundamentally different reimbursement conversation than a monthly biologic or a course of esketamine sessions. For the label, Compass now has a data-backed argument for a re-dosing protocol rather than a single-administration claim, which expands the addressable market and simplifies the treatment center economics. For the sector, a clean NDA filing in Q4 puts a psilocybin approval on the calendar for 2027, a year after the industry assumed it was dead, and it does so under an FDA and HHS leadership that has been unusually vocal about psychedelics.

The risks haven't moved: REMS design, the cost of supervised dosing infrastructure, and whether the agency accepts functional unblinding as manageable. But the durability question is now largely answered, and it was the biggest one left.

📺 Trade To Black

Democrat Calls for Full Cannabis Legalization | TDR Cannabis in 5

• Cannabis hits the Iowa Senate race: Democratic candidate Josh Turek called Schedule I "ridiculous" at an Iowa State tailgate and wants marijuana federally legalized, regulated and taxed.

• Personal, not political: Turek, who uses a wheelchair after being born with spina bifida, draws on disability advocacy and co-sponsored Iowa adult-use legislation back in 2023.

• The opponent's record is mixed: Republican Rep. Ashley Hinson voted against federal legalization in 2022 but backed cannabis banking reform in 2021.

• Iowa is moving anyway: Gov. Kim Reynolds signed a bill doubling permitted dispensaries, regulators are dropping residency requirements, and gubernatorial candidate Rob Sand wants marijuana treated like alcohol.